# Acquired BRAF V600E Mutation Mediated Resistance to Osimertinib and Responded to Osimertinib, Dabrafenib, and Trametinib Combination Therapy

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/acquired-braf-v600e-mutation-mediated-resistance-to-osimertinib-and-responded-to/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Yihua Huang,Jiadi Gan,Kunbin Guo,Yangyang Deng,Wenfeng Fang |
| Citations | 40 |
| DOI | 10.1016/j.jtho.2019.05.040 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | http://www.jto.org/article/S1556086419304617/pdf |
| OpenAlex ID | https://openalex.org/W2975708027 |
| PMID | 31558239 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Yihua Huang](https://scholariq.org/researchers/yihua-huang/)

## Paper journal

- [Journal of Thoracic Oncology](https://scholariq.org/journals/journal-of-thoracic-oncology/)

## Paper primary topic

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

## Paper topics

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.